Human Claudin-18.2 Full Length Protein (VLP)
分子別名(Synonym)
Claudin-18.2,CLDN18,Claudin-18
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Claudin-18.2 Full Length Protein-VLP (CL2-H52P7) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Val 261 (Accession # P56856-2 ).
Predicted N-terminus: Met 1
蛋白結(jié)構(gòu)(Molecular Characterization)
The protein has a calculated MW of 27.7 kDa | 56.1 kDa.
病毒樣顆粒(VLP)是由病毒的包膜/衣殼蛋白自組裝形成的。膜蛋白可以用HEK293細(xì)胞培養(yǎng)物產(chǎn)生的VLP原位構(gòu)建。這些VLP將構(gòu)象完整的膜蛋白直接集中在細(xì)胞表面,并產(chǎn)生可溶性高濃度蛋白,非常適合免疫和抗體篩選。
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
制劑(Formulation)
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
運(yùn)輸(Shipping)
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲(Storage)
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
背景(Background)
Claudins(CLDN)是一個形成緊密連接并維持上皮細(xì)胞和內(nèi)皮細(xì)胞極性的蛋白質(zhì)家族。CLDN18在胃和肺中特異性表達(dá)。在通過選擇性剪接產(chǎn)生的兩種CLDN18同種型轉(zhuǎn)錄物中,CLDN18.2是一種高選擇性的胃譜系標(biāo)記物,可決定腫瘤條件下的胃表型,而CLDN18.1是肺特異性的。CLDN18.2是一種高度選擇性的胃譜系抗原,僅在短暫分化的胃上皮細(xì)胞上表達(dá),其對抗體藥物的可及性有限。14,15 CLDN18.2在惡性轉(zhuǎn)化過程中保持不變,因此經(jīng)常顯示在人類癌癥細(xì)胞表面。
關(guān)鍵字: Claudin-18.2;Claudin-18.2蛋白;Claudin-18.2重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。